Physician profile
Vanessa Lopez
NPI 1407473846
$6,292.90
in general payments reported to CMS, 2019-2025
24 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $1,248 · 2023: $1,544 · 2024: $1,557 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,156.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,536.68 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $705.20 | 2021-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $531.20 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $529.68 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $494.23 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $268.69 | 2021-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $268.40 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $251.39 | 2023-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $238.56 | 2022-2025 | Dyanavel Xr |
| Alkermes, INC. | $205.99 | 2021-2023 | Lybalvi, Aristada |
| Corium, LLC | $199.22 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $198.29 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $142.08 | 2023-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $126.68 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $114.61 | 2022-2024 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $112.60 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $110.87 | 2022-2024 | Jornay Pm |
| Braeburn INC. | $50.63 | 2024-2025 | Brixadi |
| Lilly USA, LLC | $50.16 | 2022-2024 | Zepbound, Jardiance, Mounjaro |
| Indivior INC. | $49.41 | 2024 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $49.30 | 2024-2025 | Cobenfy |
| Biogen, INC. | $33.21 | 2024-2025 | Zurzuvae |
| Almatica Pharma LLC | $14.39 | 2023 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.